Eloralintide vs Retatrutide: What the Trials Show and Which Could Reach You First

By The RX Index Editorial Team · Last verified October 2026

Eloralintide vs retatrutide compares two experimental weekly shots. Neither is FDA-approved. Retatrutide targets three hormone signals and reported 28.3% average weight loss with 12 mg at 80 weeks in adults without diabetes. Lilly plans an FDA filing for early 2027. Eloralintide targets amylin and is also in Phase 3. No direct comparison establishes which is better.

Three things change that picture. We found no trial testing them against each other, so the comparisons below draw on separate studies. In these studies, people with type 2 diabetes lost less on both. And September's big eloralintide combination headline isn't eloralintide alone. It's eloralintide paired with tirzepatide. The tables below separate all three.

RX Index Decision Verdict: Retatrutide has more data, bigger reported numbers, and a planned FDA filing. Eloralintide is earlier, works a different way, and is being studied both alone and with other drugs. Neither is available for routine prescription purchase in the U.S.

• Best for: people following the research, deciding whether to wait, or getting ready to talk with a clinician or a trial team.
• Not ideal for: picking a dose, a seller, or a do-it-yourself combination. Trial doses are not instructions for home use.
• The factor that matters most: which legal path fits you right now, not which headline number is bigger.

Eloralintide vs retatrutide at a glance

Eloralintide and retatrutide are two different investigational medicines from Eli Lilly. They act on different hormone signals, and we found no direct trial comparison. Retatrutide is much further along: Lilly has reported five positive Phase 3 trials and a planned FDA filing, while eloralintide's Phase 3 trials are still running.

Sources: Lilly eloralintide FAQ, Lilly expanded-access page, Lilly’s five-trial update, and ClinicalTrials.gov search using both names and research codes. Checked October 15, 2026.

"Phase 3" means large studies that test treatment benefits and risks before a company seeks approval. Reaching Phase 3 does not mean a drug will be approved. (FDA trial phases)

The fair comparison: who was studied, and for how long

In the studies below, retatrutide’s highest reported average weight loss was larger than eloralintide’s in both populations. The diabetes studies also ran for different lengths. Because these are separate trials, the table shows what each drug did against its own placebo group, not a race between them.

Comparing two trials is like comparing two runners' times on different tracks on different days. You learn something real. You don't learn who would win the same race.

So we group results by diabetes status, show each trial’s length and size, and say where they differ.

*Our simple subtraction of the published, rounded averages: drug group minus that same trial's placebo group, in percentage points. It shows the placebo context, but it is not the trial’s model-based treatment difference and does not make separate trials comparable. For example, 25.0 − 3.9 = 21.1 points here; the published TRIUMPH-1 analysis reports a 21.0-point difference using its underlying estimates. The two Phase 3 figures use different analysis methods, explained below. (NEJM TRIUMPH-1 abstract)

Doses name the research groups. They are not instructions. Results are group averages, not a forecast for any one person. The participant counts in this table are whole-trial totals, not the size of each dose group.

Here's the honest limit: no comparison page, including this one, can tell you which experimental drug would work better for you. What it can do is show what was actually tested, and point you to the legal paths you can bring to your clinician. That's what the rest of this page does.

If you're reading this because you want to start treatment, not just follow the research, that's a different decision. The right GLP-1 path isn't the same for everyone. It depends on your state, your insurance and formulary (your plan's drug list), whether you want an FDA-approved or compounded medicine, a shot or a pill, and your budget. The RX Index's Find My GLP-1 Path tool is free, takes about 2 minutes, and needs no signup. You answer a few quick questions and see a suggested provider path and pricing to review. It doesn't check your plan's coverage, and it doesn't offer either of these experimental drugs. Compounded medicines are not FDA-approved.

See which GLP-1 path fits you today

How do eloralintide and retatrutide work differently?

Retatrutide is one molecule that switches on three hormone signals: GLP-1, GIP, and glucagon. Eloralintide switches on one: amylin, a hormone your pancreas releases along with insulin after you eat. They reach weight loss through different doors, and a different door doesn't prove a better result.

Think of each hormone as a key and each receptor as the lock it opens on a cell.

• GLP-1 (glucagon-like peptide-1) quiets hunger, slows how fast your stomach empties, and helps control blood sugar. Wegovy works here.
• GIP (glucose-dependent insulinotropic polypeptide) works alongside GLP-1 on blood sugar and appetite. Zepbound and Mounjaro (tirzepatide) use GLP-1 plus GIP.
• Glucagon is the third key in retatrutide. It's linked to how the body uses energy and handles liver fat.
• Amylin is part of the "that's enough, you're full" signal. Eloralintide is built to act on amylin receptors and much less on a closely related one, the calcitonin receptor.

So retatrutide turns three knobs at once. Eloralintide turns one knob that today's GLP-1 drugs don't touch. That's why Lilly is also testing eloralintide paired with tirzepatide. (Lilly eloralintide research; Lilly retatrutide research; Zepbound label, section 12; Wegovy label, section 12)

For the deeper background, see eloralintide explained, what retatrutide is, and triple vs dual agonists.

Which one causes more weight loss?

Retatrutide has reported larger average weight loss than eloralintide alone, in more people and over longer trials. In the no-diabetes studies above, the top TRIUMPH-1 result was 28.3% at 80 weeks, versus 20.1% at 48 weeks for eloralintide in Phase 2. Without a direct comparison, that shows a pattern, not a proven winner.

Three details change what a headline number means.

The same trial can report two numbers

Retatrutide's 28.3% and 25.0% come from the same 12 mg group in the same trial. They answer two different questions.

Each one is an estimand: the exact question a study's math is built to answer.

• "If everyone had stayed on treatment" (the efficacy estimand) estimates the result if all participants stayed on the study medicine, allowing specified dose changes, without starting prohibited weight-management treatments. That's the 28.3%.
• "Including treatment stops" (the treatment-regimen estimand) estimates the result regardless of whether participants stopped the study medicine or used prohibited weight-management treatments. That's the 25.0%.

Say 100 people start a trial and 15 stop the medicine along the way. The first analysis asks, "What would the result be if everyone stayed on treatment?" The second asks, "What is the result when treatment stops count too?" Both use statistical models; neither is just an average of the people who finished. The second includes a problem that occurs in everyday care, but it is still a trial estimate, not a personal forecast.

Eloralintide's 20.1% is an efficacy estimand number. Lilly hasn't published a matching treatment-regimen number in the eloralintide press releases we checked.

The 30% headline came from a selected group

You may have seen retatrutide's 30.3%. It's real. But it came from a two-year extension that enrolled 532 people who started with a BMI (body mass index, based on height and weight) of 35 or higher, finished the 80-week study, and tolerated their assigned treatment. The 30.3% was the continued-treatment estimate for the subgroup originally assigned 12 mg—not all 532 people. During the extension, they received their maximum tolerated dose of 9 or 12 mg. Everyone in the extension took retatrutide, including people who started on placebo. (Lilly, May 21, 2026)

Say you see a post putting eloralintide's 48-week result next to retatrutide's two-year extension. Before picking a winner, look at who was counted. One is a main trial result. The other is a group of people who had already stuck with the drug and handled it well. A bigger number here answers a different question.

The type 2 diabetes studies reported lower averages

Both drugs had lower reported averages in their type 2 diabetes studies than in the no-diabetes studies above. Those comparisons do not isolate diabetes as the only cause.

• Eloralintide alone: up to 12.3% at 48 weeks (6 mg). The 9 mg group averaged 11.1%, so a higher dose didn't always mean more loss.
• Retatrutide: up to 20.8% at 80 weeks (12 mg). It also lowered A1C, a measure of average blood sugar over about three months. The largest A1C drop was 1.6 percentage points at 9 mg; the 12 mg group dropped 1.5 points. The trial’s average starting A1C was 7.7%.

The diabetes trials ran for different lengths, so this row is still not a fair race. These are results in people with diabetes, not a direct comparison. (Eloralintide/EloraTZP study; TRIUMPH-2)

For the full set of numbers, see retatrutide's full weight-loss results and how to read GLP-1 trials.

Which has fewer side effects?

The evidence doesn't show that either drug is gentler. Stomach symptoms were common in both drugs' trials, and the rates varied by dose and study. Retatrutide's trials also reported unusual skin sensations called dysesthesia. Eloralintide's top weight-loss group had far more tiredness than placebo.

Read each drug row against its own trial's placebo group. These are selected events from different trials and lengths, not a complete safety comparison or a way to pick a safety winner.

Sources: Lilly ObesityWeek 2025 eloralintide slides; Lilly TRIUMPH-1 release. Different trials and lengths; not a head-to-head.

An adverse event is any health problem recorded during a study. It isn't automatically proven to be caused by the drug. That's why the placebo row matters. In the small eloralintide groups above, four people stopped for an adverse event in each group: 4 of 54 is 7.4%, while 4 of 52 is 7.7%.

Dysesthesia means unusual skin sensations, like burning or tingling. In TRIUMPH-1 it showed up in 5.1% to 12.5% of people on retatrutide, depending on dose, versus 0.9% on placebo. Lilly reported it was mostly mild to moderate and usually went away during treatment.

Two things the headlines skip:

• Eloralintide's "gentle" reputation comes from its lower doses. The small 6 mg group had the highest nausea and adverse-event stopping rates: nausea 64.3%, vomiting 25.0%, and 21.4% stopped after an adverse event. The 9 mg group, where the 20.1% came from, had tiredness in 42.6% of people.
• Dose and the trial’s step-up schedule belong beside the safety numbers. Eloralintide's slower 3 → 6 → 9 mg group had vomiting in 1.9% of people, versus 11.1% in the group that started at 9 mg. Retatrutide's 4 mg dose, reached with just one step up, had a lower adverse-event stop rate than placebo in TRIUMPH-1 (4.1% vs 4.9%). That retatrutide comparison does not isolate the effect of step-up speed.

If you've heard eloralintide is "the one without the GLP-1 nausea," the data doesn't support that yet. For more on retatrutide, see retatrutide side-effect findings.

EloraTZP vs retatrutide: is retatrutide being "dethroned"?

In people with type 2 diabetes, eloralintide plus tirzepatide (EloraTZP) averaged up to 23.3% weight loss at 48 weeks in a Phase 2b trial. Retatrutide averaged up to 20.8% at 80 weeks in a separate Phase 3 trial. Neither the weight-loss numbers nor the stopping rates prove which would work better or be easier to tolerate in the same patients.

This is the combination behind Lilly’s September 30 announcement. Both weight-loss figures below use the efficacy estimand.

Sources: Lilly EloraTZP release, Sept 30, 2026; Lilly TRIUMPH-2 release, Sept 29, 2026.

EloraTZP reported a higher weight-loss average after fewer weeks, in a smaller, earlier trial. Its highest reported stopping rate was also higher, but the ranges overlap and the placebo stopping rates differ sharply. That's promising, not a dethroning—and not proof of a safety winner. The release does not identify which combination group had the 27.0% rate.

Two points that get mixed up online:

• EloraTZP is not another name for retatrutide. It's eloralintide plus tirzepatide, the medicine in Zepbound and Mounjaro.
• EloraTZP results don't belong to eloralintide alone. In the same trial, eloralintide by itself topped out at 12.3%. Tirzepatide 15 mg alone reached 14.8%.

Which could you get first?

Retatrutide is further ahead on the announced development timeline. Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. We found no filing announcement for eloralintide. Its main Phase 3 completion estimates fall in 2028; ENLIGHTEN-1's longer follow-up extends to 2030. Neither drug has an approval date.

The dates deserve a closer look. ENLIGHTEN-1 lists March 2028 as its estimated main completion and July 2030 as overall completion, including longer follow-up. TRIUMPH-5 lists November 2026 as estimated main completion. TRANSCEND-T2D-2 lists August 27, 2026 as actual main completion, but had no posted results when checked. Both retatrutide head-to-head records were active, not recruiting. Finishing data collection is not the same as publishing results. (ENLIGHTEN-1; TRIUMPH-5; TRANSCEND-T2D-2)

A filing isn't an approval. After a company submits, the FDA reviews the benefits, risks, manufacturing, and label, and can approve, ask for more, or say no. Approval also does not guarantee a launch date, affordable pricing, or insurance coverage. (FDA review process)

For the longer access story, see retatrutide availability and our obesity drug pipeline tracker.

Can you get eloralintide or retatrutide today?

Not as a regular prescription. Neither is FDA-approved or available through routine prescribing. The verified U.S. access paths are a clinical trial for either drug, or, for retatrutide, a narrow program a doctor requests for one patient.

The retatrutide expanded-access exception

Expanded access lets some patients use an investigational drug outside a trial when they can't join one and have run out of options. For retatrutide, it's a narrow, doctor-requested program, not an early-access signup.

To be considered, Lilly's expanded-access page says a patient must meet all of these:

• Age 18 or older.
• A BMI of 35 or higher despite sticking with, and tolerating, the highest available dose of a long-term weight-management medicine.
• Two or more serious or life-threatening weight-related conditions already being treated.
• Unable to join a retatrutide trial or a trial of a similar drug, because of eligibility rules or no reasonably close site.
• All standard options, including weight-loss surgery, already discussed with their doctor.

Anyone with a medical reason not to take retatrutide is excluded. The request comes from your treating doctor, not from you. Lilly asks patients not to contact it directly.

If approved, the doctor takes on real work: becoming the sponsor of a single-patient investigational new drug application with the FDA, getting review board approval, and storing and dispensing the drug. Lilly doesn't ship directly to patients. Lilly says the drug itself is provided at no cost. That doesn't mean doctor visits, monitoring, or travel are free. Availability also depends on where you live and on supply, and the program ends after potential FDA approval and commercial availability. (Lilly Medical page last reviewed August 26, 2026; checked October 15, 2026.) The official record is NCT07629401.

We found no comparable eloralintide expanded-access program in the sponsor information and registry records checked on October 15, 2026.

"Research use only" vials and compounding

The FDA says retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. The FDA has also warned companies selling retatrutide and similar drugs "falsely labeled 'for research purposes'" to consumers with dosing instructions, and urges people not to buy them. (FDA, checked October 15, 2026)

Compounded drugs are not FDA-approved, and the FDA does not review their safety, effectiveness, or quality before marketing. The FDA's page doesn't name eloralintide. Eloralintide remains investigational. On October 15, 2026, we found no eloralintide entry in the FDA's 503A or 503B bulk-ingredient lists or the 503A and 503B nomination documents. We did not verify a lawful compounding path for it; that is separate from the FDA's explicit statement about retatrutide. A vial labeled "eloralintide" or "elora" doesn't prove what's inside, how much, or whether it's sterile. More here: how to avoid fake GLP-1 medications and our compounded GLP-1 enforcement tracker.

If you've injected a product bought online and have severe stomach pain that won't go away, vomiting you can't stop, or signs of an allergic reaction like swelling or trouble breathing, get medical care now.

Can you take eloralintide and retatrutide together, or switch between them?

We found no registered or published trial testing eloralintide and retatrutide together, or testing a switch between them. There is no established combination or switching protocol from the evidence checked. Lilly's registered combination studies pair eloralintide with tirzepatide or with another investigational drug, macupatide. (Registry search; macupatide–eloralintide study)

Both drugs' trials reported nausea, vomiting, and other stomach symptoms. The checked evidence does not establish what happens when they're combined. A plausible idea isn't evidence.

If you're on an approved weekly medicine and your weight loss has stalled, there's a better route than a home experiment. Lilly's ENLIGHTEN-6 trial studies added eloralintide or placebo in people with persistent obesity or overweight who are already on a stable weekly incretin medicine—a medicine that acts on gut-hormone signals. The listing was enrolling when checked, but a plateau alone does not establish eligibility. Ask your clinician and the study team. Never stop or change a prescription just to qualify for a trial.

Does either one protect muscle?

Neither has been shown to protect muscle better than the other. Eloralintide's "muscle-sparing" claims draw on rat research comparing it with another amylin drug. Retatrutide does have published human body-composition data, but that is not proof of superior muscle protection.

In a 36-week Phase 2 substudy in adults with type 2 diabetes, retatrutide reduced body fat. The authors reported that the share of weight loss coming from lean mass was similar to that reported with other obesity treatments. Lean mass is not the same as muscle alone; it also includes other nonfat tissues and water. This was not a comparison with eloralintide. (Retatrutide body-composition study, published online June 30, 2025; eloralintide animal-research reference in Lilly’s report)

Weight loss can include muscle loss. That's why clinical guidance stresses adequate protein and strength training. The comparison readers want—eloralintide vs retatrutide on muscle in the same people—was not found in the checked evidence. (2025 joint nutrition advisory) More here: GLP-1 lean mass by drug.

What should you do with this information?

Use the research to have a better conversation, not to pick an experimental dose or seller. The right next step depends on whether you need treatment now, want to explore a trial, or are already doing well on a current plan.

Want help starting that conversation? Copy this into your patient portal or bring it to your next visit:

I've been reading about eloralintide and retatrutide. My main concern is [weight loss stalling / side effects / staying at my goal / getting access]. Do these studies change my options right now? Would an approved treatment or a clinical trial make more sense for me? What should I bring to my next visit?

For approved options you can discuss today, see alternatives to retatrutide and is tirzepatide worth it.

For readers seeking care now, FDA-approved options already act on some of the same pathways. Tirzepatide is the other half of EloraTZP, and it's approved today as Zepbound. Whether it, Wegovy, a pill, or something else fits you depends on your insurance, budget, and health. The tool below helps compare provider paths; a licensed clinician makes treatment decisions. (Zepbound label; Wegovy label)

Compare GLP-1 paths for care now

What we actually verified

We checked the primary sources behind the study numbers and labeled the details that change their meaning. We didn't test either drug, and we can't decide who qualifies for a trial or a program.

Last verified October 2026. Source checks completed October 15, 2026:

• Lilly's reports for eloralintide Phase 2 (November 6, 2025), TRIUMPH-1 (May 21, 2026), TRIUMPH-2 and -3 (July 23, 2026), TRIUMPH-2 publication (September 29, 2026), and EloraTZP (September 30, 2026).
• Lilly's original ObesityWeek 2025 eloralintide slides, including visual checks of the dose-by-dose safety tables on PDF pages 23–24; the 2023 retatrutide Phase 2 abstract; the 2026 NEJM TRIUMPH-1 abstract and publication date; and the 2025 retatrutide body-composition abstract.
• Current Lilly study pages and ClinicalTrials.gov records for the ENLIGHTEN studies, the two retatrutide head-to-head trials, and expanded access. The expanded-access record listed the program as available, last updated August 6, 2026—not a promise that any individual patient will qualify.
• Lilly's retatrutide expanded-access page, last reviewed August 26, 2026; the FDA's current unapproved-drug guidance; and the 503A/503B lists and nomination documents for the eloralintide listing check. Trial-date and ingredient-list checks were redone, not carried forward from August.
• The relevant approved-product label sections for the brand examples, the joint nutrition advisory, and the live internal links and Find My GLP-1 Path description. We did not test a personalized tool result or re-audit every linked RX Index article.

What these sources are: most numbers come from Lilly's own reports, which are primary sources but not independent confirmation. We worked from accessible abstracts, registry records, original presentation tables, and sponsor reports—not complete journal full texts. Our placebo-subtraction column uses rounded published means, not the trials' full statistical models.

What we couldn't confirm: a routine retail price or insurance coverage for either investigational drug, any approval or launch date, total care costs under expanded access, or whether a trial site near you has open spots. Lilly's no-cost expanded-access statement applies to the medicine itself. Searches that found no direct comparison, combination, or switching study cannot rule out unpublished or differently indexed research.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

This page uses an RX Index Decision Verdict, not a provider score. Our methodology explains the distinction.

Frequently asked questions

Is eloralintide the same as retatrutide?

No. They're different molecules. Eloralintide acts on amylin receptors, while retatrutide acts on GLP-1, GIP, and glucagon receptors. Both are investigational once-weekly shots from Eli Lilly, but neither is a brand name for the other.

Which is better, eloralintide or retatrutide?

No direct trial establishes which is better. Retatrutide has reported more weight loss in separate trials, has Phase 3 results, and has a planned FDA filing. Eloralintide works a different way, and its Phase 3 studies are still running.

Is EloraTZP better than retatrutide?

Not proven. EloraTZP, eloralintide plus tirzepatide, reached up to 23.3% at 48 weeks in people with type 2 diabetes, versus retatrutide's 20.8% at 80 weeks in a separate trial. EloraTZP adverse-event stopping rates ranged from 10.8% to 27.0%, versus 16.7% for its placebo group; separate studies cannot establish which treatment is easier to tolerate. Lilly plans Phase 3 testing of a one-shot formulation by the end of 2026.

Can you take eloralintide and retatrutide together?

We found no registered or published study of this combination, so there is no established safe combination protocol in the evidence checked. Lilly's registered combination studies pair eloralintide with tirzepatide or macupatide. Those findings do not support adding retatrutide yourself.

Can you switch from retatrutide to eloralintide?

We found no trial testing a switch between them. Neither is routinely prescribed, but retatrutide does have a narrow physician-requested expanded-access program outside clinical trials. For people on a stable weekly incretin with persistent obesity, ENLIGHTEN-6 studies add-on treatment—not a switch from retatrutide to eloralintide.

Does retatrutide or eloralintide preserve muscle?

Neither has been shown to preserve muscle better than the other. Eloralintide's muscle claims draw on rat research. Retatrutide has human body-composition data, but the reported share of weight loss from lean mass was similar to other obesity treatments, not proof of a muscle-sparing advantage.

Which has fewer side effects?

Neither has been shown to be gentler in a direct comparison. Nausea was common in both drugs' trials, with rates varying by dose and study. Retatrutide's trials reported unusual skin sensations (dysesthesia), and eloralintide's 9 mg group had tiredness in 42.6% of people.

When will eloralintide and retatrutide be available?

Neither has an approval or launch date. Lilly plans to submit retatrutide to the FDA in the first quarter of 2027. Eloralintide's main Phase 3 completion estimates are in 2028; ENLIGHTEN-1 has longer follow-up through 2030, and no filing has been announced. Trial dates and filing plans are not approval forecasts.

Can either one be compounded?

The FDA says retatrutide cannot be used in compounding under federal law. Eloralintide remains investigational, and our October 15, 2026 check found no entry in the FDA ingredient lists and nomination documents reviewed; we did not verify a lawful compounding path for it. A research-use label does not make either product an authorized patient treatment.

Is either one a pill?

No. Both are given as once-weekly shots under the skin in Lilly's trials. A website listing either one as a pill isn't describing the drug Lilly is studying.

What do "elora" and "reta" mean?

They are shorthand for eloralintide and retatrutide. Neither medicine is FDA-approved. A seller using those names does not prove that a vial contains the medicine used in Lilly's trials.

Sources

Checked October 15, 2026. Publication, document-update, and source-check dates are different and are labeled separately. Journal sources below were checked through their accessible abstracts and publisher details, not complete full texts.

1. Eli Lilly and Company. Eloralintide Phase 2 results, November 6, 2025. investor.lilly.com
2. Eli Lilly and Company. Eloralintide Phase 2 symposium slides, ObesityWeek 2025. PDF
3. Eli Lilly and Company. EloraTZP Phase 2b results, September 30, 2026. investor.lilly.com
4. Eli Lilly and Company. What to know about eloralintide, updated September 2026. lilly.com
5. Eli Lilly and Company. ENLIGHTEN-1 study page (NCT07321886). trials.lilly.com
6. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. N Engl J Med. 2023. PubMed
7. Eli Lilly and Company. TRIUMPH-1 results, May 21, 2026. investor.lilly.com
8. Jastreboff AM, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. Published online September 29, 2026. nejm.org
9. Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 results, July 23, 2026. investor.lilly.com
10. Eli Lilly and Company. TRIUMPH-2 results published in The Lancet, September 29, 2026. investor.lilly.com
11. Lilly Medical. Is there an expanded access program for retatrutide? Last reviewed August 26, 2026. medical.lilly.com
12. ClinicalTrials.gov. Pre-approval expanded access of retatrutide (NCT07629401). clinicaltrials.gov
13. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Current page checked October 15, 2026. fda.gov
14. ClinicalTrials.gov. TRIUMPH-5, retatrutide compared with tirzepatide (NCT06662383). clinicaltrials.gov
15. ClinicalTrials.gov. TRANSCEND-T2D-2, retatrutide compared with semaglutide (NCT06260722). clinicaltrials.gov
16. ClinicalTrials.gov. ENLIGHTEN-1 (NCT07321886). Main completion estimated March 2028; overall completion estimated July 2030; record updated September 22, 2026. Study record
17. ClinicalTrials.gov and Lilly. ENLIGHTEN-6 (NCT07392190), add-on eloralintide in people on a stable weekly incretin. Record updated September 22, 2026. Registry; sponsor study page
18. ClinicalTrials.gov. ENLIGHTEN-2 (NCT07282600), obesity/overweight with type 2 diabetes. Record updated October 8, 2026. Study record
19. ClinicalTrials.gov. Search for both drug names and research codes; no matching record returned on October 15, 2026. Search
20. ClinicalTrials.gov. Macupatide and eloralintide, alone or in combination (NCT07589608). Study record
21. Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13:674–684. Published online June 30, 2025. PubMed abstract
22. The Obesity Society, American Society for Nutrition, Obesity Medicine Association, and American College of Lifestyle Medicine. Nutritional priorities to support GLP-1 therapy for obesity: joint advisory, 2025. Society summary
23. U.S. Food and Drug Administration / eCFR. 503A bulk-drug rules and permitted list (21 CFR 216.23); 503B bulk list. 503A rules; 503A list; 503B list
24. U.S. Food and Drug Administration. Bulk-drug nomination documents: 503A, updated May 14, 2026; 503B, updated March 21, 2025. Both checked October 15, 2026. 503A PDF; 503B PDF
25. U.S. Food and Drug Administration. Clinical research phases and drug-application review. Clinical research; FDA review
26. Eli Lilly and Company; Novo Nordisk. Current Zepbound and Wegovy prescribing information, relevant indications, mechanism, and safety sections. These labels concern the approved products, not eloralintide or retatrutide. Zepbound; Wegovy